Asia Genomics to develop longevity tech with foreign company
28 Jun 2016, Canis Inculta
Finding the secret to longevity
Insilico Medicine Inc. and Asia Genomics (AG) have announced a partnership to develop advanced longevity suites catered to age-related conditions. The partnership aims to improve personalised healthcare systems to provide for elderly services.
Insilico is a big data analytics firm from Johns Hopkins University, while AG is a Singapore-based research firm specialising in clinical genomics and genetic testing operating in Asian countries like China, Vietnam, and Malaysia.
AG has developed innovative solutions for personalised healthcare worldwide. By establishing research partnerships, they can test practical applications to be translated into clinical practice.
AG founder and CEO Dr. Wong Mun Yew says they were glad to be collaborating with Insilico Medicine, known as one of the leaders in applying artificial intelligence to drug discovery and aging research.
The cooperative venture will ultimately bring the power of molecular biology technologies such as genomics to Asia, allowing their partners and customers understand more about their health and longevity along with possible ways for intervention, he added.
AG is developing a programme for longevity science in Singapore with strategic expansions to different countries in Asia. It uses state-of-the-art genetic testing to develop personalised health and longevity plans to maximise life potential.
The companies have agreed to develop advanced personal longevity suites to help identify ageing-related markers based on individual age genomic and personal specific transcriptomic information.
Furthermore, the two companies are developing an artificially intelligent age prediction algorithm to accord with Deep Neural Networks tested for Asian biochemical samples.
Genomics may hold the key to life expansion. In the past few years, American researchers were able to monitor supercentenarians and their possible hereditary source. Scientists were able to discover genome sequencing as a possible method for age extension.
According to the World Health Organization, global life expectancy is reflected in the overall mortality of a population from birth. Life expectancy in Asia varies from 60 to 80 years of age. This information holds a key factor on the importance of how personalised health procedures should be provided.
For his part, Insilico CEO Alex Zhavoronkov said Asia Genomics is one of the leading molecular diagnostics and genomics company in Asia with state-of-the-art equipment and highly qualified staff educated in top international universities.
The company represents the growing power of molecular biology technologies in Asia and is close to becoming the next Asian biotechnology unicorn.
Zhavoronkov added his company was honoured to have been selected as one of the providers of high-technology solutions for personalized longevity research.